GZMB and Sepsis: In 28-day nonsurvivors, a trend of decreasing plasma granzyme B levels during treatment was observed, distinct from survivors, highlighting the greater clinical significance of baseline granzyme B levels in sepsis prognosis compared to short-term changes following treatment.